Purpose: The purpose of this study was to develop a radiobiological model of reoxygenation that fulfills the following goals: (a) Quantify the reoxygenation effect for different fractionations (b) Model the hypoxic fraction in tumors as a function of the number of radiation treatments. (c) Develop a simple analytical expression for a reoxygenation term in biological effect calculations. Method: The model considers tumor cells in two compartments: an aerobic (or normoxic) population of cells and a hypoxic population including cells under a range of reduced oxygen concentrations. The surviving fraction is predicted using the linear-quadratic (LQ) model. A hypoxia reduction factor (HRF) is used to quantify reductions in radiosensitivity parameters a A and b A as cellular oxygen concentration decreases. The HRF is defined as the ratio of the dose at a specific level of hypoxia to the dose under fully aerobic conditions to achieve equal cell killing. The model assumes that a fraction of the hypoxic cells (D) moves from the hypoxic to the aerobic compartment after each daily fraction. As an example, we compare the effect of reoxygenation on biological response for a standard dose fractionation for nonsmall cell lung cancer (NSCLC) (d = 2 Gy, n = 33) to typical fractionations for stereotactic body radiotherapy (SBRT) and other nonstandard fractionations. Results: The reoxygenation effect is parameterized for biological effect calculations and an analytic expression for the surviving fraction after n daily treatments is derived. The hypoxic fraction either increases or decreases with n depending on the reoxygenation parameter D. For certain combinations of parameters, the biological effect of reoxygenation goes as À(nÀ1) Á ln(1ÀD) providing a simple expression that can be introduced in biologically effective dose (BED) calculations. The model is used to compare fractionation schedules and quantitatively interpret results from molecular imaging studies of hypoxia. Based on the comparison of conventional fractionation and hypo-and hyper-fractionation for NSCLC, the value of D is estimated to be between 0.1 and 0.2 assuming plausible radiobiological parameters from the literature. This value is consistent with the preliminary analysis of the molecular imaging studies. Conclusions: A novel radiobiological model was developed that can be used to evaluate the effect of reoxygenation in fractionated radiotherapy.
INTRODUCTION
The identification of an optimal time course for radiotherapy to improve clinical outcomes has been a long-standing problem in radiation oncology. In particular, the problem of biological optimization of fractionations schedules can be addresses using quantitative radiobiological modeling. Several authors have tackled this important question by developing expressions for the biologically effective dose (BED) delivered to tumors and normal tissues with the objective of minimizing the normal tissue BED while keeping the tumor BED constant (see for example references 1-4 and references therein). Many clinical implementations of BED modeling based on the linear-quadratic (LQ) model explicitly include the effect of tumor cell repopulation 1, 2 while others ignore the effect. 3, 4 However, none of these works address the potential impact of tumor hypoxia or the effect of tumor cell reoxygenation. While it is known that hypoxia is an important factor that can limit tumor control and that the reoxygenation effect can favor fractionation schedules with larger number of fractions, there is no simple way to include these effects in BED expressions of different fractionation schedules. A closed formula for the biological effect that includes hypoxia and reoxygenation effects could help address this limitation.
In recent years, there have been several molecular imaging studies that investigated changes in hypoxia during fractionated radiotherapy. 5, 6 For example, in a prospective cohort study, Bollineni et al. 5 used serial 18 F-FAZA PET imaging to investigate the spatio-temporal dynamics of tumor hypoxia in head and neck (H&N) and lung cancer patients, and track changes in tumor hypoxic fractions during fractionated radiotherapy. Carlson 
and collaborators
† performed serial 18 F-FMISO PET imaging of tumor hypoxia in early stage nonsmall cell lung cancer (NSCLC) patients undergoing stereotactic body radiation therapy (SBRT) and identified the potential for substantial variation in tumor hypoxic fractions post-SBRT. In order to interpret these reported clinical observations, a more complete model of BED that includes tumor hypoxia and reoxygenation is needed.
The purpose of this work is to develop a radiobiological model of tumor hypoxia and reoxygenation with a closed formula for the surviving fraction of cells and changes in the hypoxic fraction during fractionated radiotherapy. The model can be used to interpret results from clinical molecular imaging studies, to calculate the contribution of reoxygenation in protracted radiation treatments, and to develop a simple formula that includes reoxygenation in biological effects calculations.
METHOD AND MATERIALS
Tumor cells are classified into two compartments: an aerobic compartment with fraction f A of the total number of clonogenic cells and surviving fraction S(d) A and a hypoxic compartment with fraction f H = 1Àf A of clonogenic cells and surviving fraction S(d) H , where d is the dose per fraction. The surviving fraction of cells after dose d is estimated using the Linear-Quadratic (LQ) model S(d) = e Ànd(a + bd) assuming complete repair between acute fractions. The a and b parameters in the aerobic and the hypoxic compartments can be related by a Hypoxia Reduction Factor (HRF). 7, 8 The HRF is defined as the ratio of the dose at a specific level of hypoxia to the dose under fully aerobic conditions to achieve equal cell killing 7, 8 so that a A = a H Á HRF and The model assumes a certain fraction D of the remaining hypoxic cells after each radiation treatment fraction of dose d, moves from the hypoxic compartment to the aerobic compartment. We assume D is constant but the possibility of variations after each fraction is also considered. We use the concept of biological effect E d; n ð Þ ¼ ÀlnðS d; n ð ÞÞ, where n is the total number of daily fractions d. We isolate the reoxygenation biological effect by dividing S(d,n) by the surviving fraction with no reoxygenation (D = 0) and define E reox ðd; nÞ ¼ Àln½S d; n ð Þ=S no reox ðd; nÞ. We also define the biological effect per fraction as e(d, n) = E(d, n) À E(d, nÀ1). As an example of a possible application of the model, we compare E(d, n) for different fractionations of NSCLC with the repopulation biological effect as E repop n ð Þ ¼ Àð1:4n À T k Þlnð2Þ=T d , where T d is the potential doubling time and T k is the onset of rapid repopulation. We use radiobiological parameters for NSCLC from the literature 9 : a = 0.35 Gy À1 a/b = 10 Gy, T k = 28 days (assuming no repopulation occurs when total treatment time T < T k ) and T d = 5, 3, or 2 days. We approximate T as 1.4 Á n assuming daily fractions delivered during the work week. The repopulation effect is only included for conventional fractionations with daily treatments since treatment times for other fractionations are less than 28 days. As a starting point, we assume f H = 0.2 and HRF = 1.5 based on a previous study 7 suggesting an average of HRF of ≤ 1.5 derived from clinical data. The average value of HRF is meant to represent both extreme and intermediate levels of hypoxia. We look at the effect of varying D which is defined as the fraction of hypoxic cells that reoxygenate after each fraction, i.e., move from the hypoxic to aerobic cell component. Specifically, we compare a standard fractionation for NSCLC (d = 2 Gy, n = 33) to Stereotactic Body Radiation Therapy (SBRT) and other nonstandard fractionations. As another possible application of the model, we use it to interpret molecular imaging studies of NSCLC patients.
2.A. Closed formula for the surviving fraction of cells including the effect of reoxygenation
After n daily fractions of dose d, the overall surviving fraction of cells S(d, n) neglecting cellular proliferation is (see Appendix A for derivation, Eq. (A13):
where
Equation (1) represents a closed formula for the surviving fraction that allows us to extract the important parameters in the problem by simple examination. The first term represents the tumor cells that always remain hypoxic, the second term represents the aerobic cells that started in the aerobic compartment, and the last term represents cells that were originally in the hypoxic compartment but re-oxygenated (i.e., moved to the aerobic compartment) over the course of treatment. The parameter g SðdÞ H represents surviving fraction of cells that are hypoxic during the entire course of radiotherapy or the 'persistently' hypoxic cells. The (1ÀD) factor represents the fraction of hypoxic cells that remain in the hypoxic compartment after each treatment and mathematically acts as a "sensitizer parameter" by reducing the effective surviving fraction of the hypoxic cells. The parameter k is the ratio between the surviving fraction of cells that are always aerobic and the surviving fraction of cells that are always hypoxic and its value is indicative of whether the hypoxic cells dominate survival. It is useful to factor out the surviving fraction of persistently hypoxic cell population in Equation (1):
The biological effect E(d, n) = Àln(S(d, n)) can then be written as:
2.B. Reoxygenation biological effect
The impact of the biological effect of reoxygenation can be conveniently evaluated by examining the ratio of the biological effect with and without reoxygenation, i.e., E reox (d,
where 
2.C. Hypoxic fraction
The hypoxic fraction can be written as the ratio of the number of hypoxic cells to the number of total surviving cells:
On the basis of Eq. (7), we can make the following observations regarding the hypoxic fraction:
1. For k < 1 and fractionated treatments with large n, the hypoxic fraction asymptotically reaches the value:
The asymptotic value of the hypoxic fraction is independent of the initial value of f H and depends instead on the ratio of surviving fractions in the two compartments and the reoxygenation parameter D. If there was no reoxygenation, the asymptotic value of the hypoxic fraction is 1, since the aerobic cells would die-off after a few initial fractions, which is a well-known result. When there is no reoxygenation (D = 0), the hypoxic fraction always increases monotonically with the number of fractions due to the fact that a larger proportion of aerobic cells are killed because they are more radiosensitive. When there is reoxygenation (D > 0), if D is smaller than a critical value D C the hypoxic fraction also increases with the number of fractions, but when D becomes larger than D C the hypoxic fraction will decrease with n. The critical value D C can be derived by taking the derivative with respect to n of f H (d, n) in Eq. (7) and equating it to 0 which gives:
2.D. Analysis of molecular imaging studies of hypoxia during fractionated treatments
As an example of an application to molecular imaging studies using 18F-FAZA PET/CT images, we use our model to interpret results reported by Bollineni et al., 5 who performed longitudinal studies of changes in the fractional hypoxic volume of the tumor during fractionated treatment (equivalent to our definition of f H (d,n)). Bollineni et al. 5 performed 18 F-FAZA PET/CT scans for NSCLC and head and neck cancer patients treated with chemoradiation before treatment (baseline), after the second week of treatment (n = 10), and after the 4th week of treatment (n = 20). Based on previous studies, they defined the hypoxic volume as the region exhibiting a tumor-to-background (T/B) ratio greater than 1.4. Changes in voxel-by-voxel values were tracked, and the authors observed that some voxels that started hypoxic or aerobic remain the same throughout the treatment, but some voxels that started hypoxic became aerobic and some that started aerobic became hypoxic. While our model only considers cells moving from the hypoxic compartment to the aerobic one, the reoxygenation parameter D can be interpreted as representative of a net "gain" of cells going from the hypoxic compartment to the aerobic one, which assumes an overall reoxygenation effect in the tumor.
In the voxel-by-voxel analysis of Bollineni et. al., 5 the methodology for image registration between the 18 F-FAZA PET/CT and the original planning CT is critical because knowledge of voxel-to-voxel correspondence is needed. Bollineni et al. 5 used MIM Vista software (MIM corp., Version 6.1, Cleveland, OH, USA) to analyze the original planning 18 F-FDG PET/CT data and define the gross tumor volume using a threshold of 34% for the NSCLC tumors and 40% for H&N tumors. To register the subsequent 18 F-FAZA PET/CTs, they used a free-form deformable image registration module from MIM Vista for a CT-CT registration (after a first rigid registration step). For the current analysis with our two-compartment model, the details of the image registration process have a small impact, although they are provided by Bollineni et al. 6 In this study, we assume a uniform dose distribution across all tumor voxels, which is reasonable for standard fractionation treatments. We therefore do not need to associate each voxel in the PET/CT evaluation scans with the original planning CT to obtain the dose. Furthermore, since the only information from the images used in this study is the hypoxic fraction, as long as the overall tumor volume is correctly identified in each PET/CT, the hypoxic fraction is calculated by simply counting the voxels with uptake values larger than 1.4 and dividing by the total number of voxels in the tumor. Therefore, a voxel-to-voxel correspondence is not needed. In the case of SBRT treatments (not included in this study), the assumption of uniform dose across the tumor may be violated since large heterogeneity in dose is often used. For such cases, an equivalent uniform dose (EUD) would have to be used or an extension of the model would have to be considered, where different doses for different parts of the tumor are allowed.
The six NSCLC patients analyzed had stage III or IV NSCLC and were treated with concurrent chemotherapy. The ages ranged from 50 to 71 yr of age (median 62) and tumor size ranged from 22 to 70 cc (median 48 cc). For more details of patient characteristics, please see Table Ib of the original study of Bollineni et al. Table I shows the values of the total reoxygenation biological effect E reox (d, n) for several different fractionation schedules used in NSCLC with the same parameters for both the full model and the approximate expression. Table I shows that, even for modest values of the parameter D, the full expression may be needed when comparing different fractionation schedules particularly when hyperfractionation is being considered because the approximate expression tends to overestimate the total reoxygenation effect. Table I also shows that the standard fractionation schedule can have a similar (or larger) reoxygenation effect compared to the hyperfractionation regimen when D is large enough, i.e., ≥ 0.2. This is despite having fewer fractions than the hyperfractionation scheme and assuming the same D value for both cases. In addition, it is biologically plausible that the hyperfractionation scheme could have a smaller fraction of cells D moving from the hypoxic to aerobic component given the reduced time between fractions and the reduced dose per fraction in hyperfractionation schemes.
3.B. Hypoxic fraction
Using Eq. (7) it is possible to calculate the changes in hypoxic fraction during a fractionated treatment. Figure 2 shows hypoxic fraction versus n for the NSCLC parameters described in the methods section for three different values of the reoxygenation parameter D, demonstrating two different scenarios (the hypoxic fraction increases with n for small D or decreases with n for larger values of D) and the special case where D = D C and the hypoxic fraction remains constant [i.e., D = 0.214 based on Eq. (9)]. The case of D = 0 is also included for reference.
3.C. Application to NSCLC fractionation comparison
As an example of a possible application of the model we consider a comparison between standard fractionation treatments versus (SBRT) and two hyperfractionation schedules: the Continuous Hyperfractionated Accelerated Radiotherapy (CHART) 10 and its dose-escalated version, CHART weekend-less (CHARTWEL). 11 While the comparison of different fractionation schedules for NSCLC has been investigated in many studies, few have considered the effect of tumor hypoxia, reoxygenation, and tumor cell proliferation.
Using the parameters described in the methods section with f H = 0.2 (based on reference [7] and references therein), we considered the following treatment schedules: • Standard fractionation for NSCLC (d = 2 Gy, n = 33 or n = 30).
• SBRT: (n = 1, d = 24-34 Gy), (n = 3, d = 18 Gy), (n = 4, d = 12 Gy) (n = 5, d = 10 Gy).
• CHART (n = 36, d = 1.5 in 12 days).
• CHARTWEL (n = 40, d = 1.5 in 18 days).
Since the assumed value for the onset of repopulation was 28 days, the repopulation effect was only relevant for the standard fractionation regimen with total treatment times greater than 28 days. Table II A smaller value of D is also consistent with the fact that CHART was more effective clinically than the conventional schedule (with 30 fractions) in terms of both local control and overall survival. 10 The CHARTWEL schedule was compared to a conventional schedule with 33 fractions and it was found to have a trend to slightly higher local control overall (P = 0.23) and a significantly higher local control for advanced stages of NSCLC (P < 0.05).
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Therefore also a value of D less than 0.3 is consistent with this result for an HRF of 1.5 and the assumed values of parameters. The first column of Table II shows the biological effect without hypoxia (HRF = 1, and therefore no reoxygenation) nor repopulation; in that case, the hypofractionated schedules are significantly more effective than the conventional or hyperfractionated schedules. In the case of hyperfractionated schedules it is possible that a smaller value of D should be used since less time between fractions may translate to a smaller re-oxygenated fraction. However, for simplicity we assumed that D was the same for all schedules.
3.D. Application to molecular imaging studies of hypoxia during fractionated treatments
We consider, for our example, the 6 NSCLC patients reported in Bollineni et al. 5 study and use the same parameters as in sections 3.B and 3.C. Four of the six NSCLC patients had the hypoxic fraction measured both after the second and after the fourth week of treatment. They had an If we use the initial value of f H for each patient as an input parameter, it is possible to get an approximate estimate for the reoxygenation parameter D, based on the values at 2 weeks, 4 weeks or both using Eq. (7) for f H (d, n). For the first patient with
This rapid reduction in the hypoxic fraction points to a value of D = 0.5 suggesting a large reoxygenation effect. For the patient that starts at 0.3% hypoxic fraction, which stays at 2% after 2 weeks and 0 after 4 weeks, hypoxia does not really play a significant role and our model is not relevant in that case. The third patient has f H = 0.63, f H (d = 2Gy, n = 10) = 0.26 and f H (d = 2Gy, n = 20) = 0.46. In this case, the hypoxic fraction decreases during the first 2 weeks but then increases after two more weeks. To interpret such case, we would have to introduce a reoxygenation parameter that changes during treatment. One way to approach it is to calculate D for the first 2 weeks and then use the 2-week value of f H as the initial value and look for D that would give the 4 week f H 2 weeks later. With that method we obtain D = 0. 
DISCUSSION
Hypoxia and reoxygenation are well known phenomena affecting the biological effect of radiation treatments. It is common in the literature, however, to ignore one or both of these effects when performing modeling studies that compare or optimize different fractionation schedules.
1-4,9,12 Brenner et al. 13 proposed a formula for including reoxygenation/ resensitization in the LQ model assuming a distribution of values of a, but the model was designed to describe surviving fraction changes with time between two fractions separated by a few hours rather than different fractionation schedules. Our model is different in that it neglects inter/intra patient variations among the LQ parameters a and b and assumes that a certain fraction of existing hypoxic cells take part in the TABLE II. Comparison of the total biological effect and the reoxygenation biological effect for a conventional NSCLC fractionation schedule with a few clinically used SBRT schedules and the CHART and CHARTWEL schedules. The (*) signals that repopulation was included in the total biological effect of the conventional schedule. reoxygenation effect between daily, twice a day or three times a day fractions. Other authors have proposed dividing the tumor in two compartments with different radiosensitivity to model hypoxia (see for example, Lind and Brahme 14 ) and other heterogeneities in the tumor, but have not developed closed formulas for the overall surviving fraction or the hypoxic fraction as a function of n when reoxygenation effects are present. Carlson et al. 7 developed a sophisticated model of hypoxia and reoxygenation but considered only the case where f H (d,n) remains constant throughout the treatment which may not be a correct assumption (but is a special case of our model).
We have developed a closed formula for the surviving fraction, the total biological effect, the reoxygenation biological effect and the hypoxic fraction as a function of n. We have also found that under certain conditions where the hypoxic cells dominate, the biological effect of reoxygenation has a simple expression proportional to the ln(1ÀD), independent of HRF, dose per fraction d, and the LQ parameters a and b. However, the simplified formula may lead to an over-estimation of the total reoxygenation biological effect of up to almost 50% (based on Table I , for assumed NSCLC parameters). The simplified formula can be used to roughly estimate the gain in biological effect by adding a daily fraction as compared to the loss due to repopulation. After the onset of rapid repopulation, an additional day of treatment gives a loss of biological effect of DE repop = ln (2) While we have assumed that the same fraction D of existing hypoxic cells moves to the aerobic compartment after each treatment of dose d, the model can be easily extended for cases where D changes. The approximate expression is easily extended by simply considering the average <ln (1ÀD)> over n fractions or equivalently, the geometric average of (1ÀD). The full model is more challenging to generalize, because the geometric sum no longer applies, however, the expression can be left as an explicit sum (see Appendix, A14).
We have shown the application of the proposed model for the comparison of different fractionation schedules for NSCLC radiotherapy. On the basis of the presented results, we estimate a value of D to be less than 0.3 to be consistent with clinical experience of SBRT, CHART and CHARTWEL trials. This estimate of D is contingent on the assumed radiobiological parameters, which were derived without the consideration of inter-patient variation in tumor hypoxia or the reoxygenation effect, and therefore have an inherent limitation.
We have also shown that our model can be used to interpret molecular imaging studies of hypoxia during treatment. It is likely that similar studies will become available in the near future. Our model provides a tool that can help with the quantitative analysis of the imaging data of such studies.
The model proposed in this work should be interpreted as a possible starting point for the study of reoxygenation and fractionation effects. Besides simplifying the problem to a two-compartment model, we assumed that the fraction D of hypoxic cells that move to the aerobic compartment is constant, independent of dose per fraction and time between fractions. In reality, these assumptions may be violated given the variety of processes involved in reoxygenation with different time scales and dose dependence. 15 The fraction dose and time-dependence of this parameter must be explored in future studies in both animal models and human tumors.
CONCLUSIONS
A closed formula for the surviving fraction of tumor cells as a function of number of fractions n is proposed that can be used for biological effect calculations and optimization of radiation fractionation. The hypoxic fraction increases or decreases with n depending on the assumed value of the reoxygenation parameter D. A comparison of radiotherapy schedules and estimation based on molecular imaging studies suggest a small value of D.
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Again, before the next treatment, a fraction D of the existing hypoxic cells (last term in A3) moves to the aerobic compartment:
